Farallon Capital Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Farallon Capital Management’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-100,000	Closed	-$2.92M	–	106
2018 Q4	$2.92M	Sell	100,000 -113,663	-53%	-$5.04M	0.02%	91
2018 Q3	$13.2M	Buy	213,663 +13,663	+7%	+$925K	0.08%	81
2018 Q2	$14.8M	Buy	+200,000	New	+$15.6M	0.09%	68

Other funds holding BLCM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Farallon Capital Management's BLCM Position: Q1 2019 in Review

Farallon Capital Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2019, closing a stake of 100,000 shares — an estimated $2.92M sold.

Farallon Capital Management first reported a position in BLCM in Q2 2018 and held it in 3 quarters. The position peaked at $14.8M in Q2 2018. 94 funds tracked by Wall St. Rank hold BLCM as of Q1 2019.

Farallon Capital Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
Farallon Capital Management sold 100,000 Bellicum Pharmaceuticals, Inc. shares in Q1 2019, an estimated $2.92M.
Farallon Capital Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q2 2018 and held it in 3 quarters.
Farallon Capital Management's Bellicum Pharmaceuticals, Inc. position peaked at $14.8M in Q2 2018.
94 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2019.

Based on Farallon Capital Management's 13F filing for Q1 2019, filed 15 May 2019.